9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BRAF plays an indispensable role in activating the MEK/ERK pathway to drive tumorigenesis. Receptor tyrosine kinase and RAS-mediated BRAF activation have been extensively characterized, however, it remains undefined how BRAF function is fine-tuned by stimuli other than growth factors. Here, we report that in response to proinflammatory cytokines, BRAF is subjected to lysine 27-linked poly-ubiquitination in melanoma cells by the ITCH ubiquitin E3 ligase. Lysine 27-linked ubiquitination of BRAF recruits PP2A to antagonize the S365 phosphorylation and disrupts the inhibitory interaction with 14–3–3, leading to sustained BRAF activation and subsequent elevation of the MEK/ERK signaling. Physiologically, proinflammatory cytokines activate ITCH to maintain BRAF activity and to promote proliferation and invasion of melanoma cells, whereas the ubiquitination-deficient BRAF mutant displays compromised kinase activity and reduced tumorigenicity. Collectively, our study reveals a pivotal role for ITCH-mediated BRAF ubiquitination in coordinating the signals between cytokines and the MAPK pathway activation in melanoma cells.

          Abstract

          BRAF drives MEK/ERK activation to facilitate tumorigenesis. Here, the authors show that in response to pro-inflammatory cytokines, ITCH mediates a non-proteolytic ubiquitination and activation of BRAF, which in turn sustains MEK/ERK signaling to facilitate melanoma cell growth.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

          Systematic analyses of cancer genomes promise to unveil patterns of genetic alterations linked to the genesis and spread of human cancers. High-density single-nucleotide polymorphism (SNP) arrays enable detailed and genome-wide identification of both loss-of-heterozygosity events and copy-number alterations in cancer. Here, by integrating SNP array-based genetic maps with gene expression signatures derived from NCI60 cell lines, we identified the melanocyte master regulator MITF (microphthalmia-associated transcription factor) as the target of a novel melanoma amplification. We found that MITF amplification was more prevalent in metastatic disease and correlated with decreased overall patient survival. BRAF mutation and p16 inactivation accompanied MITF amplification in melanoma cell lines. Ectopic MITF expression in conjunction with the BRAF(V600E) mutant transformed primary human melanocytes, and thus MITF can function as a melanoma oncogene. Reduction of MITF activity sensitizes melanoma cells to chemotherapeutic agents. Targeting MITF in combination with BRAF or cyclin-dependent kinase inhibitors may offer a rational therapeutic avenue into melanoma, a highly chemotherapy-resistant neoplasm. Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.

            Recent pre-clinical and clinical research has provided evidence that cancer progression is driven not only by a tumour's underlying genetic alterations and paracrine interactions within the tumour microenvironment, but also by complex systemic processes. We review these emerging paradigms of cancer pathophysiology and discuss how a clearer understanding of systemic regulation of cancer progression could guide development of new therapeutic modalities and efforts to prevent disease relapse following initial diagnosis and treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diversity of degradation signals in the ubiquitin-proteasome system.

              The ubiquitin-proteasome system degrades an enormous variety of proteins that contain specific degradation signals, or 'degrons'. Besides the degradation of regulatory proteins, almost every protein suffers from sporadic biosynthetic errors or misfolding. Such aberrant proteins can be recognized and rapidly degraded by cells. Structural and functional data on a handful of degrons allow several generalizations regarding their mechanism of action. We focus on different strategies of degron recognition by the ubiquitin system, and contrast regulatory degrons that are subject to signalling-dependent modification with those that are controlled by protein folding or assembly, as frequently occurs during protein quality control.
                Bookmark

                Author and article information

                Contributors
                lixin.wan@moffitt.org
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                23 April 2019
                23 April 2019
                2019
                : 10
                : 1870
                Affiliations
                [1 ]ISNI 0000 0000 9891 5233, GRID grid.468198.a, Department of Molecular Oncology, , H. Lee Moffitt Cancer Center and Research Institute, ; Tampa, FL 33612 USA
                [2 ]ISNI 0000 0000 9891 5233, GRID grid.468198.a, Proteomics and Metabolomics Core, , H. Lee Moffitt Cancer Center and Research Institute, ; Tampa, FL 33612 USA
                [3 ]ISNI 0000 0000 9891 5233, GRID grid.468198.a, Department of Thoracic Oncology, , H. Lee Moffitt Cancer Center and Research Institute, ; Tampa, FL 33612 USA
                [4 ]ISNI 0000 0000 9891 5233, GRID grid.468198.a, Department of Tumor Biology, , H. Lee Moffitt Cancer Center and Research Institute, ; Tampa, FL 33612 USA
                [5 ]ISNI 0000 0001 2353 285X, GRID grid.170693.a, Department of Chemistry, , University of South Florida, ; Tampa, FL 33620 USA
                [6 ]ISNI 0000 0004 1758 3257, GRID grid.459518.4, Department of Oncology, , Jining First People’s Hospital, ; Jining, Shandong 272111 P.R. China
                [7 ]ISNI 0000 0001 2353 285X, GRID grid.170693.a, Department of Cell Biology, , Microbiology, and Molecular Biology, University of South Florida, ; Tampa, FL 33620 USA
                [8 ]ISNI 0000 0000 9891 5233, GRID grid.468198.a, Department of Cutaneous Oncology, , H. Lee Moffitt Cancer Center and Research Institute, ; Tampa, FL 33612 USA
                Author information
                http://orcid.org/0000-0002-7636-1318
                http://orcid.org/0000-0001-8034-6762
                http://orcid.org/0000-0002-3818-1762
                Article
                9844
                10.1038/s41467-019-09844-0
                6478693
                31015455
                732993bf-03c7-4d1a-a9c8-a9c40c1cbe0f
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 2 July 2018
                : 29 March 2019
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                biochemistry,proteins,ubiquitins,ubiquitylated proteins,cancer
                Uncategorized
                biochemistry, proteins, ubiquitins, ubiquitylated proteins, cancer

                Comments

                Comment on this article